Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareFirst H.P. Acthar Gel Retired Policy Update | …
    Ask Trek AI about this page
    RetiredCareFirstPolicy N/A

    Repository Corticotropin Injection (H.P. Acthar Gel) — RETIRED

    Customize your policy alerts

    Sign up for all CareFirst policy alerts

    Know when CareFirst releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs coverage and administrative handling for repository corticotropin injection (H.P. Acthar Gel) and informs providers that the policy is retired; it affects providers submitting drug prior authorization requests to CareFirst.

    Policy Summary
    PayerCareFirst
    PolicyRepository Corticotropin Injection (H.P. Acthar Gel) — RETIRED
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionSubmit all drug prior authorization requests electronically via CareFirst Direct and contact CVS Specialty Pharmacy for specialty drug questions.
    SourceLink
    POLICY UPDATE CHANGES

    The active policy statement and coverage criteria for repository corticotropin injection have been retired.

    Providers must submit all drug prior authorization requests electronically per the notification effective January 1, 2017.

    RetiredPolicy status
    Jan 1, 2017

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Electronic PA since
    CVSSpecialty contact
    ListedReferences

    Coverage Criteria and Policy Stance

    Coverage stance: This policy is retired. There is no active policy statement or medical necessity criteria provided for repository corticotropin injection (H.P. Acthar Gel) in this document; providers should refer to other current policies or clinical guidance for coverage determinations.

    Exclusions and NMN: The retired policy contains no explicit exclusions and provides no explicit not medically necessary (NMN) conditions. Administrative instructions remain in effect—providers must follow electronic prior authorization procedures when submitting requests for this drug.

    Coding and Billing

    No codes specifiedmixed
    No codes listed
    Coding (ancillary)
    Coding statusNo procedure, diagnosis, or billing codes are specified in this retired policy.
    Code groupsNone listed; coding group labeled 'No codes specified' in the document.
    ThresholdsNone
    Action for providersContinue to follow electronic prior authorization procedures for drug submissions as described in Provider Guidelines.

    Provider Actions and Prior Authorization

    Prior Authorization

    Electronic prior authorization — submit via CareFirst Direct

    Prior authorization for repository corticotropin injection is handled electronically. Submit PA requests through CareFirst Direct and contact CVS Specialty Pharmacy for questions about covered specialty drugs.

    • If already registered for CareFirst Direct: log in at www.carefirst.com/providerlogin and click the Prior Auth/Notification tab.
    • If not registered: go to www.carefirst.com/provider and click Register Now.
    • For specialty drug questions: call CVS Specialty Pharmacy at 855-264-3237.
    Step Therapy

    Step therapy — none specified

    This retired policy does not specify any step therapy requirements.

    Background and Clinical Context

    H.P. Acthar Gel (repository corticotropin injection) is described as a naturally derived, highly purified sterile preparation of adrenocorticotropic hormone (ACTH) formulated in gelatin to provide prolonged release after subcutaneous or intramuscular injection. It stimulates adrenal cortical production of endogenous steroids and is pharmacologically distinct from synthetic diagnostic agents such as cosyntropin.

    The active policy statement and coverage criteria for this drug have been retired; this document serves as informational background on the product formulation and general properties rather than as an active coverage guideline.

    Definitions

    Repository corticotropin injection — definition and description
    TermRepository corticotropin injection (H.P. Acthar Gel)
    DefinitionA naturally derived, highly purified sterile preparation of adrenocorticotropic hormone (ACTH) in 16% gelatin to provide prolonged release after subcutaneous or intramuscular injection.
    Pharmacologic actionStimulates the adrenal cortex to secrete cortisol, corticosterone, and other hormones; increases endogenous steroid production (actions similar to corticosteroids).
    Regulatory/status noteThis medical policy is retired; providers must submit all drug prior authorization requests electronically per the notification effective Jan. 1, 2017.
    Cosyntropin — definition and distinction
    TermCosyntropin

    Site of Care

    Note

    No infusion center/site-of-care restrictions

    This retired policy does not specify any site-of-care or infusion center restrictions.

    Policy Summary
    PayerCareFirst
    PolicyRepository Corticotropin Injection (H.P. Acthar Gel) — RETIRED
    Policy CodePolicy N/A
    Change TypeRetired
    Effective DateFeb 1, 2026
    Last ReviewNov 12, 2025
    Next Review DateNov 12, 2025
    Key ActionSubmit all drug prior authorization requests electronically via CareFirst Direct and contact CVS Specialty Pharmacy for specialty drug questions.
    SourceLink
    On This Page
    Coverage Criteria and Policy StanceCoding and BillingProvider Actions and Prior AuthorizationBackground and Clinical ContextDefinitionsSite of Care
    Documentation Required

    Electronic prior authorization required — register or log in

    Providers must submit all drug prior authorization requests electronically via CareFirst Direct; register for CareFirst provider access if not already registered. Links and instructions are provided on the CareFirst provider site.

    • Registered providers: log in at www.carefirst.com/providerlogin and use the Prior Auth/Notification tab to begin the request.
    • Unregistered providers: go to www.carefirst.com/provider and click Register Now.
    • Provider forms and additional instructions: https://provider.carefirst.com/providers/pharmacy/pharmacy-forms.page
    Denial Risk

    Denial triggers — none specified

    No explicit denial triggers are identified in this retired policy document.

    DefinitionA synthetic form of ACTH that is injected intravenously and is used for diagnostic testing of adrenocortical function.
    DistinctionCosyntropin is pharmacologically and clinically distinct from repository corticotropin injection (H.P. Acthar Gel) and should not be confused with it.